CA2373990C
(en)
*
|
1999-05-21 |
2007-05-08 |
Bristol-Myers Squibb Company |
Pyrrolotriazine inhibitors of kinases
|
WO2001014378A1
(fr)
*
|
1999-08-23 |
2001-03-01 |
Shionogi & Co., Ltd. |
DERIVES DE PYRROLOTRIAZINE A ACTIVITES INHIBANT sPLA¿2?
|
JP2004505965A
(ja)
*
|
2000-08-09 |
2004-02-26 |
アストラゼネカ アクチボラグ |
化合物
|
ATE448226T1
(de)
|
2000-09-01 |
2009-11-15 |
Novartis Vaccines & Diagnostic |
Aza heterocyclische derivate und ihre therapeutische verwendung
|
US20030028018A1
(en)
*
|
2000-09-11 |
2003-02-06 |
Chiron Coporation |
Quinolinone derivatives
|
ATE309996T1
(de)
|
2000-09-11 |
2005-12-15 |
Chiron Corp |
Chinolinonderivate als tyrosin-kinase inhibitoren
|
US6867300B2
(en)
|
2000-11-17 |
2005-03-15 |
Bristol-Myers Squibb Company |
Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors
|
US6670357B2
(en)
*
|
2000-11-17 |
2003-12-30 |
Bristol-Myers Squibb Company |
Methods of treating p38 kinase-associated conditions and pyrrolotriazine compounds useful as kinase inhibitors
|
PT1363910E
(pt)
*
|
2000-11-17 |
2006-05-31 |
Bristol Myers Squibb Co |
Metodos para o tratamento de estados patologicos associados as cinases p38 e compostos de pirrolotriazina uteis como inibidores de cinases
|
US6699890B2
(en)
|
2000-12-22 |
2004-03-02 |
Memory Pharmaceuticals Corp. |
Phosphodiesterase 4 inhibitors
|
KR100856622B1
(ko)
*
|
2001-01-22 |
2008-09-03 |
메모리 파마슈티칼스 코포레이션 |
포스포디에스테라제 4 억제제
|
US7205320B2
(en)
|
2001-01-22 |
2007-04-17 |
Memory Pharmaceuticals Corp. |
Phosphodiesterase 4 inhibitors
|
US7153871B2
(en)
|
2001-01-22 |
2006-12-26 |
Memory Pharmaceuticals Corporation |
Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
|
TW200300350A
(en)
*
|
2001-11-14 |
2003-06-01 |
Bristol Myers Squibb Co |
C-5 modified indazolylpyrrolotriazines
|
US6900208B2
(en)
|
2002-03-28 |
2005-05-31 |
Bristol Myers Squibb Company |
Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
|
SE0200979D0
(sv)
*
|
2002-03-28 |
2002-03-28 |
Astrazeneca Ab |
New compounds
|
SE0302546D0
(sv)
|
2003-09-24 |
2003-09-24 |
Astrazeneca Ab |
New compounds
|
FR2838123B1
(fr)
*
|
2002-04-04 |
2005-06-10 |
Sanofi Synthelabo |
Nouveaux derives d'indolozine-1,2,3 substituee, inhibiteurs selectifs du b-fgf
|
CN102093363B
(zh)
|
2002-04-23 |
2016-12-07 |
布里斯托尔-迈尔斯斯奎布公司 |
可用作激酶抑制剂的吡咯并三嗪苯胺化合物
|
US7388009B2
(en)
|
2002-04-23 |
2008-06-17 |
Bristol-Myers Squibb Company |
Heteroaryl-substituted pyrrolo-triazine compounds useful as kinase inhibitors
|
PL373371A1
(en)
*
|
2002-04-23 |
2005-08-22 |
Bristol-Myers Squibb Company |
Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
|
TW200400034A
(en)
|
2002-05-20 |
2004-01-01 |
Bristol Myers Squibb Co |
Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
|
AU2003236557B2
(en)
*
|
2002-06-27 |
2009-10-01 |
Verva Pharmaceuticals Pty Ltd |
Differentiation modulating agents and uses therefor
|
TWI329112B
(en)
*
|
2002-07-19 |
2010-08-21 |
Bristol Myers Squibb Co |
Novel inhibitors of kinases
|
TWI272271B
(en)
*
|
2002-07-19 |
2007-02-01 |
Bristol Myers Squibb Co |
Process for preparing certain pyrrolotriazine compounds
|
EP1539697A1
(en)
|
2002-07-19 |
2005-06-15 |
Memory Pharmaceutical Corporation |
Phosphodiesterase 4 inhibitors, including n-substituted aniline and diphenylamine analogs
|
AU2003256601B2
(en)
|
2002-07-19 |
2009-10-29 |
Memory Pharmaceuticals Corporation |
6-amino-1H-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
|
KR100869417B1
(ko)
*
|
2002-07-19 |
2008-11-21 |
브리스톨-마이어스 스큅 컴퍼니 |
신규한 키나제 억제제
|
EP1388541A1
(en)
*
|
2002-08-09 |
2004-02-11 |
Centre National De La Recherche Scientifique (Cnrs) |
Pyrrolopyrazines as kinase inhibitors
|
AU2003288899B2
(en)
|
2002-08-23 |
2009-09-03 |
Novartis Vaccines And Diagnostics, Inc. |
Benzimidazole quinolinones and uses thereof
|
US7087625B2
(en)
|
2002-11-19 |
2006-08-08 |
Memory Pharmaceuticals Corporation |
Phosphodiesterase 4 inhibitors
|
TW200420565A
(en)
*
|
2002-12-13 |
2004-10-16 |
Bristol Myers Squibb Co |
C-6 modified indazolylpyrrolotriazines
|
KR20050099525A
(ko)
|
2003-02-05 |
2005-10-13 |
브리스톨-마이어스 스큅 컴퍼니 |
피롤로트리아진 키나제 억제제의 제조 방법
|
US7102001B2
(en)
|
2003-12-12 |
2006-09-05 |
Bristol-Myers Squibb Company |
Process for preparing pyrrolotriazine
|
US7064203B2
(en)
*
|
2003-12-29 |
2006-06-20 |
Bristol Myers Squibb Company |
Di-substituted pyrrolotriazine compounds
|
MY145634A
(en)
*
|
2003-12-29 |
2012-03-15 |
Bristol Myers Squibb Co |
Pyrrolotriazine compounds as kinase inhibitors
|
AP2139A
(en)
|
2004-04-02 |
2010-08-21 |
Osi Pharm Inc |
6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors.
|
US7459562B2
(en)
|
2004-04-23 |
2008-12-02 |
Bristol-Myers Squibb Company |
Monocyclic heterocycles as kinase inhibitors
|
TW200538453A
(en)
|
2004-04-26 |
2005-12-01 |
Bristol Myers Squibb Co |
Bicyclic heterocycles as kinase inhibitors
|
UY28931A1
(es)
*
|
2004-06-03 |
2005-12-30 |
Bayer Pharmaceuticals Corp |
Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
|
US7102002B2
(en)
*
|
2004-06-16 |
2006-09-05 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
US7439246B2
(en)
|
2004-06-28 |
2008-10-21 |
Bristol-Myers Squibb Company |
Fused heterocyclic kinase inhibitors
|
US20050288290A1
(en)
|
2004-06-28 |
2005-12-29 |
Borzilleri Robert M |
Fused heterocyclic kinase inhibitors
|
US7432373B2
(en)
|
2004-06-28 |
2008-10-07 |
Bristol-Meyers Squibb Company |
Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
|
TW200600513A
(en)
|
2004-06-30 |
2006-01-01 |
Bristol Myers Squibb Co |
A method for preparing pyrrolotriazine compounds
|
US7102003B2
(en)
*
|
2004-07-01 |
2006-09-05 |
Bristol-Myers Squibb Company |
Pyrrolotriazine compounds
|
MY139689A
(en)
|
2004-07-20 |
2009-10-30 |
Osi Pharm Inc |
Imidazotriazines as protein kinase inhibitors
|
US7504521B2
(en)
|
2004-08-05 |
2009-03-17 |
Bristol-Myers Squibb Co. |
Methods for the preparation of pyrrolotriazine compounds
|
US7148348B2
(en)
|
2004-08-12 |
2006-12-12 |
Bristol-Myers Squibb Company |
Process for preparing pyrrolotriazine aniline compounds useful as kinase inhibitors
|
EP1812439B2
(en)
†
|
2004-10-15 |
2017-12-06 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
US7151176B2
(en)
*
|
2004-10-21 |
2006-12-19 |
Bristol-Myers Squibb Company |
Pyrrolotriazine compounds
|
US7759337B2
(en)
|
2005-03-03 |
2010-07-20 |
Amgen Inc. |
Phthalazine compounds and methods of use
|
US7534882B2
(en)
|
2005-04-06 |
2009-05-19 |
Bristol-Myers Squibb Company |
Method for preparing pyrrolotriazine compounds via in situ amination of pyrroles
|
AR056968A1
(es)
|
2005-04-11 |
2007-11-07 |
Xenon Pharmaceuticals Inc |
Compuestos espiro-oxindol y composiciones farmacéuticas
|
MY145694A
(en)
|
2005-04-11 |
2012-03-30 |
Xenon Pharmaceuticals Inc |
Spiroheterocyclic compounds and their uses as therapeutic agents
|
KR100695700B1
(ko)
*
|
2005-04-20 |
2007-03-15 |
김세중 |
조립식 경량벽체 패널과 그 조립구조
|
KR100672087B1
(ko)
*
|
2005-04-25 |
2007-01-19 |
재단법인 포항산업과학연구원 |
폐단형 스터드부재 및 이를 이용한 단열 벽체 시스템
|
BRPI0610355A2
(pt)
|
2005-05-17 |
2010-06-15 |
Novartis Ag |
métodos par sintetizar compostos heterocìclicos
|
US7576082B2
(en)
*
|
2005-06-24 |
2009-08-18 |
Hoffman-La Roche Inc. |
Oxindole derivatives
|
US7402582B2
(en)
*
|
2005-07-01 |
2008-07-22 |
Bristol-Myers Squibb Company |
Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
|
US7405213B2
(en)
*
|
2005-07-01 |
2008-07-29 |
Bristol-Myers Squibb Company |
Pyrrolotriazine compounds useful as kinase inhibitors and methods of treating kinase-associated conditions therewith
|
ATE543914T1
(de)
|
2005-09-01 |
2012-02-15 |
Bristol Myers Squibb Co |
Biomarker und verfahren zur bestimmung der empfindlichkeit gegen vegfr2 modulator.
|
US7880004B2
(en)
|
2005-09-15 |
2011-02-01 |
Bristol-Myers Squibb Company |
Met kinase inhibitors
|
EP1926996B1
(en)
|
2005-09-20 |
2011-11-09 |
OSI Pharmaceuticals, Inc. |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
US7547782B2
(en)
|
2005-09-30 |
2009-06-16 |
Bristol-Myers Squibb Company |
Met kinase inhibitors
|
US8431695B2
(en)
|
2005-11-02 |
2013-04-30 |
Bayer Intellectual Property Gmbh |
Pyrrolo[2,1-f][1,2,4]triazin-4-ylamines IGF-1R kinase inhibitors for the treatment of cancer and other hyperproliferative diseases
|
US7514435B2
(en)
*
|
2005-11-18 |
2009-04-07 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
US7348325B2
(en)
|
2005-11-30 |
2008-03-25 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
PE20070855A1
(es)
|
2005-12-02 |
2007-10-14 |
Bayer Pharmaceuticals Corp |
Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
|
AR057960A1
(es)
|
2005-12-02 |
2007-12-26 |
Osi Pharm Inc |
Inhibidores de proteina quinasa biciclicos
|
CA2631741C
(en)
*
|
2005-12-02 |
2014-01-28 |
Bayer Healthcare Llc |
Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
|
US8063208B2
(en)
|
2006-02-16 |
2011-11-22 |
Bristol-Myers Squibb Company |
Crystalline forms of (3R,4R)-4-amino-1-[[4-[(3-methoxyphenyl)amino]pyrrolo[2,1-f][1,2,4]triazin-5-yl]methyl]piperidin-3-ol
|
JP5399900B2
(ja)
|
2006-06-30 |
2014-01-29 |
メルク・シャープ・アンド・ドーム・コーポレーション |
Igfbp2インヒビター
|
EP2041138B1
(en)
|
2006-07-07 |
2014-06-25 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
WO2008021859A1
(en)
|
2006-08-09 |
2008-02-21 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
US7531539B2
(en)
|
2006-08-09 |
2009-05-12 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
US8466188B2
(en)
|
2006-10-12 |
2013-06-18 |
Xenon Pharmaceuticals Inc. |
Use of spiro-oxindole compounds as therapeutic agents
|
US7982033B2
(en)
|
2006-11-03 |
2011-07-19 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
US8268998B2
(en)
|
2006-11-03 |
2012-09-18 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
EP2111402B1
(en)
*
|
2007-01-05 |
2012-03-07 |
Bristol-Myers Squibb Company |
Aminopyrazole kinase inhibitors
|
EP2134875A2
(en)
|
2007-04-13 |
2009-12-23 |
Brystol-Myers Squibb Company |
Biomarkers and methods for determining sensitivity to vascular endothelial growth factor receptor-2 modulators
|
EP2134716A1
(en)
|
2007-04-18 |
2009-12-23 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
AU2008304620A1
(en)
|
2007-09-25 |
2009-04-02 |
Bayer Healthcare Llc |
Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase
|
CA2701128A1
(en)
|
2007-10-01 |
2009-04-09 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of fibroblast growth factor receptor 4 expression
|
RU2010120674A
(ru)
|
2007-10-22 |
2011-11-27 |
Шеринг Корпорейшн (US) |
Полностью человеческие анти-vegf-антитела и способы их применения
|
CN101965350A
(zh)
|
2008-01-11 |
2011-02-02 |
纳科法尔马有限公司 |
作为抗癌剂的新的吡唑并[3,4-d]嘧啶衍生物
|
ES2413806T3
(es)
|
2008-03-20 |
2013-07-17 |
Amgen Inc. |
Moduladores de la aurora cinasa y método de uso
|
US9126935B2
(en)
|
2008-08-14 |
2015-09-08 |
Amgen Inc. |
Aurora kinase modulators and methods of use
|
WO2010042684A1
(en)
*
|
2008-10-08 |
2010-04-15 |
Bristol-Myers Squibb Company |
Pyrrolotriazine kinase inhibitors
|
WO2010042649A2
(en)
|
2008-10-10 |
2010-04-15 |
Amgen Inc. |
PHTHALAZINE COMPOUNDS AS p38 MAP KINASE MODULATORS AND METHODS OF USE THEREOF
|
US8772481B2
(en)
|
2008-10-10 |
2014-07-08 |
Amgen Inc. |
Aza- and diaza-phthalazine compounds as P38 map kinase modulators and methods of use thereof
|
CA2741024A1
(en)
|
2008-10-17 |
2010-04-22 |
Xenon Pharmaceuticals Inc. |
Spiro-oxindole compounds and their use as therapeutic agents
|
NZ592275A
(en)
|
2008-10-17 |
2013-04-26 |
Xenon Pharmaceuticals Inc |
Spiro-oxindole compounds and their use as therapeutic agents
|
CA2742986C
(en)
|
2008-11-07 |
2015-03-31 |
Triact Therapeutics, Inc. |
Use of catecholic butane derivatives in cancer therapy
|
EP2376491B1
(en)
|
2008-12-19 |
2015-03-04 |
Cephalon, Inc. |
Pyrrolotriazines as alk and jak2 inhibitors
|
TW201036614A
(en)
|
2008-12-30 |
2010-10-16 |
Arqule Inc |
Substituted 1H-pyrazolo[3,4-d]pyrimidine-6-amine compounds
|
US20120189641A1
(en)
|
2009-02-25 |
2012-07-26 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
EP2400990A2
(en)
|
2009-02-26 |
2012-01-04 |
OSI Pharmaceuticals, LLC |
In situ methods for monitoring the emt status of tumor cells in vivo
|
US8642834B2
(en)
|
2009-02-27 |
2014-02-04 |
OSI Pharmaceuticals, LLC |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
WO2010099138A2
(en)
|
2009-02-27 |
2010-09-02 |
Osi Pharmaceuticals, Inc. |
Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
|
JP2012519282A
(ja)
|
2009-02-27 |
2012-08-23 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
間葉様腫瘍細胞またはその生成を阻害する薬剤を同定するための方法
|
WO2010126960A1
(en)
|
2009-04-29 |
2010-11-04 |
Locus Pharmaceuticals, Inc. |
Pyrrolotriazine compounds
|
AR077252A1
(es)
|
2009-06-29 |
2011-08-10 |
Xenon Pharmaceuticals Inc |
Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
|
SI2464232T1
(sl)
|
2009-08-10 |
2016-03-31 |
Samumed, Llc. |
Indazolovi inhibitorji signalne poti WNT in njihova terapevtska uporaba
|
BR112012008993A2
(pt)
|
2009-10-14 |
2015-09-22 |
Xenon Pharmaceuticals Inc |
métodos sintéticos para compostos espiro-oxindole
|
US8088815B2
(en)
|
2009-12-02 |
2012-01-03 |
Hoffman-La Roche Inc. |
Spiroindolinone pyrrolidines
|
NO3001903T3
(no)
|
2009-12-21 |
2018-03-24 |
|
|
US8288431B2
(en)
|
2010-02-17 |
2012-10-16 |
Hoffmann-La Roche Inc. |
Substituted spiroindolinones
|
NZ601667A
(en)
|
2010-02-26 |
2014-10-31 |
Xenon Pharmaceuticals Inc |
Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
|
CA2783665A1
(en)
|
2010-03-03 |
2011-09-09 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
|
JP2013527748A
(ja)
|
2010-03-03 |
2013-07-04 |
オーエスアイ・ファーマシューティカルズ,エルエルシー |
インスリン様増殖因子1受容体キナーゼ阻害剤に対する抗癌反応の予測に役立つ生物学的マーカー
|
US20130005733A1
(en)
|
2010-03-09 |
2013-01-03 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
US8217044B2
(en)
|
2010-04-28 |
2012-07-10 |
Hoffmann-La Roche Inc. |
Spiroindolinone pyrrolidines
|
CN102971323A
(zh)
*
|
2010-05-28 |
2013-03-13 |
拜奥克里斯特制药公司 |
作为janus激酶抑制剂的杂环化合物
|
US20120214830A1
(en)
|
2011-02-22 |
2012-08-23 |
OSI Pharmaceuticals, LLC |
Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma
|
AU2012232670A1
(en)
|
2011-03-23 |
2013-09-12 |
Ariel-University Research And Development Company Ltd. |
Treatment of proliferative disorders with a chemiluminescent agent
|
EP2702173A1
(en)
|
2011-04-25 |
2014-03-05 |
OSI Pharmaceuticals, LLC |
Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
|
CN103597074A
(zh)
|
2011-06-16 |
2014-02-19 |
Isis制药公司 |
成纤维细胞生长因子受体4表达的反义调节
|
ES2598027T3
(es)
*
|
2011-07-01 |
2017-01-24 |
Bayer Intellectual Property Gmbh |
Pirrolotriazinas sustituidas con hidroximetilarilo como inhibidores de ALK1
|
MX362494B
(es)
|
2011-09-14 |
2019-01-21 |
Samumed Llc |
Indazol-3-carboxamidas y su uso como inhibidores de la trayectoria de señalizacion de wnt/b-catenina.
|
UY34484A
(es)
*
|
2011-12-15 |
2013-07-31 |
Bayer Ip Gmbh |
Benzotienilo-pirrolotriazinas disustituidas y sus usos
|
CN104159900B
(zh)
*
|
2011-12-15 |
2016-08-24 |
拜耳知识产权有限责任公司 |
取代的苯并噻吩基-吡咯并三嗪及其在癌症治疗中的用途
|
US9475815B2
(en)
|
2012-02-23 |
2016-10-25 |
Bayer Intelletual Property Gmbh |
Substituted benzothienyl-pyrrolotriazines and uses thereof
|
PH12017500997A1
(en)
|
2012-04-04 |
2018-02-19 |
Samumed Llc |
Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
|
WO2013152252A1
(en)
|
2012-04-06 |
2013-10-10 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
CN102675323B
(zh)
*
|
2012-06-01 |
2014-04-09 |
南京药石药物研发有限公司 |
吡咯并[2,1-f][1,2,4]三嗪衍生物及其抗肿瘤用途
|
WO2014082230A1
(zh)
*
|
2012-11-28 |
2014-06-05 |
上海希迈医药科技有限公司 |
吡咯并三嗪类衍生物、其制备方法及其在医药上的应用
|
US9908867B2
(en)
|
2013-01-08 |
2018-03-06 |
Samumed, Llc |
3-(benzoimidazol-2-yl)-indazole inhibitors of the Wnt signaling pathway and therapeutic uses thereof
|
WO2014115171A1
(en)
*
|
2013-01-24 |
2014-07-31 |
Council Of Scientific & Industrial Research |
Triazine compounds and a process for preparation thereof
|
EP2961412A4
(en)
|
2013-02-26 |
2016-11-09 |
Triact Therapeutics Inc |
CANCER THERAPY
|
ES2616026T3
(es)
*
|
2013-03-11 |
2017-06-09 |
Bristol-Myers Squibb Company |
Pirrolopiridazinas como inhibidores de canales de iones potasio
|
CN105026399B
(zh)
*
|
2013-03-11 |
2017-06-23 |
百时美施贵宝公司 |
作为钾离子通道抑制剂的吡咯并三嗪类化合物
|
US9050345B2
(en)
|
2013-03-11 |
2015-06-09 |
Bristol-Myers Squibb Company |
Pyrrolotriazines as potassium ion channel inhibitors
|
US9499522B2
(en)
|
2013-03-15 |
2016-11-22 |
Blueprint Medicines Corporation |
Compositions useful for treating disorders related to kit
|
CA2923667A1
(en)
|
2013-09-09 |
2015-03-12 |
Triact Therapeutics, Inc. |
Cancer therapy
|
PL3057969T3
(pl)
|
2013-10-17 |
2018-11-30 |
Blueprint Medicines Corporation |
Kompozycje użyteczne do leczenia zaburzeń związanych z KIT
|
WO2015058129A1
(en)
|
2013-10-17 |
2015-04-23 |
Blueprint Medicines Corporation |
Compositions useful for treating disorders related to kit
|
WO2015081783A1
(zh)
*
|
2013-12-06 |
2015-06-11 |
江苏奥赛康药业股份有限公司 |
吡咯并[2,1-f][1,2,4]三嗪类衍生物及其制备方法和用途
|
CN104725381B
(zh)
*
|
2013-12-19 |
2018-04-10 |
南京圣和药业股份有限公司 |
生长因子受体抑制剂及其应用
|
US9388239B2
(en)
|
2014-05-01 |
2016-07-12 |
Consejo Nacional De Investigation Cientifica |
Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B
|
US9688680B2
(en)
|
2014-08-04 |
2017-06-27 |
Blueprint Medicines Corporation |
Compositions useful for treating disorders related to kit
|
WO2016040181A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
WO2016040185A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
|
WO2016040180A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
WO2016040193A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
|
WO2016040188A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
WO2016040182A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
|
WO2016040190A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
|
WO2016040184A1
(en)
|
2014-09-08 |
2016-03-17 |
Samumed, Llc |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
|
WO2016127068A1
(en)
|
2015-02-05 |
2016-08-11 |
Teva Pharmaceuticals International Gmbh |
Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound
|
CN104876935B
(zh)
*
|
2015-05-18 |
2017-04-19 |
南方医科大学 |
2‑氨基吡咯并[1,2‑f][1,2,4]三嗪类化合物、合成方法及应用
|
BR112018001190A2
(pt)
|
2015-07-24 |
2018-09-11 |
Blueprint Medicines Corp |
composições úteis para tratar distúrbios relacionados a kit e pdfgr
|
US10226453B2
(en)
|
2015-08-03 |
2019-03-12 |
Samumed, Llc |
3-(1H-indol-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
US10350199B2
(en)
|
2015-08-03 |
2019-07-16 |
Samumed, Llc |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
|
WO2017023986A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc |
3-(1h-indol-2-yl)-1h-indazoles and therapeutic uses thereof
|
WO2017023972A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
WO2017024025A1
(en)
|
2015-08-03 |
2017-02-09 |
Sunil Kumar Kc |
3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
US10231956B2
(en)
|
2015-08-03 |
2019-03-19 |
Samumed, Llc |
3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
|
US10285982B2
(en)
|
2015-08-03 |
2019-05-14 |
Samumed, Llc |
3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
WO2017023984A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
|
WO2017023996A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
|
WO2017024015A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
WO2017023987A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
|
WO2017024004A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
US10392383B2
(en)
|
2015-08-03 |
2019-08-27 |
Samumed, Llc |
3-(1H-benzo[d]imidazol-2-yl)-1H-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
WO2017023975A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
|
US10166218B2
(en)
|
2015-08-03 |
2019-01-01 |
Samumed, Llc |
3-(1H-indol-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
|
US10463651B2
(en)
|
2015-08-03 |
2019-11-05 |
Samumed, Llc |
3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-indazoles and therapeutic uses thereof
|
WO2017023988A1
(en)
|
2015-08-03 |
2017-02-09 |
Samumed, Llc. |
3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
|
WO2017079759A1
(en)
|
2015-11-06 |
2017-05-11 |
Samumed, Llc |
2-(1h-indazol-3-yl)-3h-imidazo[4,5-c]pyridines and their anti-inflammatory uses thereof
|
BR112018072039B1
(pt)
*
|
2016-04-28 |
2023-12-26 |
Takeda Pharmaceutical Company Limited |
Composto, medicamento, e, uso do composto ou sal do mesmo
|
EP3464285B1
(en)
|
2016-06-01 |
2022-09-21 |
BioSplice Therapeutics, Inc. |
Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide
|
AU2017345699A1
(en)
|
2016-10-21 |
2019-05-16 |
Samumed, Llc |
Methods of using indazole-3-carboxamides and their use as Wnt/B-catenin signaling pathway inhibitors
|
WO2018085865A1
(en)
|
2016-11-07 |
2018-05-11 |
Samumed, Llc |
Single-dose, ready-to-use injectable formulations
|
KR102398659B1
(ko)
|
2017-03-17 |
2022-05-16 |
주식회사 대웅제약 |
카이네이즈 저해제로서의 피롤로트리아진 유도체
|
US11040979B2
(en)
|
2017-03-31 |
2021-06-22 |
Blueprint Medicines Corporation |
Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR
|
EP3782998B1
(en)
*
|
2018-04-16 |
2023-05-10 |
Shenzhen TargetRx, Inc. |
Substituted pyrrolotriazine compound, pharmaceutical composition thereof and use thereof
|
MA55604A
(fr)
|
2019-04-12 |
2022-02-16 |
Blueprint Medicines Corp |
Dérivés de pyrrolotriazine pour le traitement de maladies médiées par kit et pdgfra
|
MA53759A
(fr)
|
2019-04-12 |
2021-08-04 |
Blueprint Medicines Corp |
Formes cristallines de (s)-1-(4-fluorophényl)-1-(2-(4-(6-(1-méthyl-1h-pyrazol-4-yl))pyrrolo[2,1-f][1,2,4]triazin-4-yl)pipérazinyl)-pyrimidin-5-yl)éthan-1-amine et des procédés de fabrication
|
WO2021094209A1
(en)
|
2019-11-12 |
2021-05-20 |
Bayer Aktiengesellschaft |
Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
|